Vitamin D and Chronic Pain
Chronic pain — persisting or recurring for more than 3 months — affects one in five adults. Vitamin D deficiency is common in chronic pain populations and, in a subset, is a directly correctable contributor. The most consistent evidence is for musculoskeletal pain and diabetic neuropathy; general fibromyalgia and neuropathic pain evidence is weaker.
Deficiency prevalence in chronic pain clinics
Multiple observational studies from pain clinics find 50–75% of chronic pain patients have 25(OH)D < 30 ng/mL, and a substantial minority < 20 ng/mL. Deficiency correlates with pain intensity, functional disability, and reduced quality of life across pain diagnoses.
The mechanism gap
Vitamin D influences neuromodulation at multiple sites — modulating nerve growth factor, TRPV1 sensitivity, cytokine production, and mitochondrial function in pain-associated tissues. Whether these mechanisms translate to clinical pain relief depends on the underlying pain generator: osteomalacia-type pain responds well to correction; neuropathic pain from other causes responds less.
Trial evidence by condition
- Diabetic peripheral neuropathy — Ghadiri-Anari 2019: 50,000 IU weekly × 8 weeks reduced neuropathic pain scores significantly vs placebo.
- Chronic musculoskeletal pain — 2015 meta-analysis showed significant pain reduction favouring vitamin D, biggest effect in patients starting deficient.
- Fibromyalgia — mixed results; Wepner 2014 showed pain and functional benefit; larger 2020 review inconclusive. See our fibromyalgia page.
- Post-surgical pain — small RCTs of preoperative repletion suggest reduced acute post-op opioid use.
- Chronic pelvic pain (non-endometriosis) — limited evidence.
Opioid-sparing potential
Small studies have hinted that correcting vitamin D deficiency may reduce opioid requirements in chronic pain patients. The mechanism could be direct pain modulation or indirect via mood and sleep improvement. In the context of the opioid crisis, this is a low-risk intervention worth including in any multimodal pain plan for deficient patients.
Practical approach
- All chronic pain patients — test 25(OH)D once.
- Correct deficiency: 2,000–4,000 IU/day for 8–12 weeks, then re-test.
- Reassess pain in 6–12 weeks — expect partial improvement in 30–50% of the deficient patients; do not expect much in the vitamin D-replete.
- Vitamin D is one component of multimodal chronic pain care (physical therapy, cognitive-behavioural therapy for chronic pain, appropriate pharmacotherapy).